Condition: Hepatocellular Carcinoma · Sponsor: AstraZeneca
Italian multicenter observational study to evaluate time to clinical hepatic decompensation, quality of life, effectiveness, and safety of tremelimumab plus durvalumab in patients with advanced or unresectable hepatocellular carcinoma who have received no prior systemic treatment.
This description comes directly from the study's public registry record.
AstraZeneca Clinical Study Information Center AstraZeneca Clinical Study Information Center · +1877240 · information.center@astrazeneca.com
Always discuss trial participation with your own doctor first.
| Research site | Ancona, Italy | Active Not Recruiting |
| Research Site | Ancona, Italy | Recruiting |
| Research Site | Bergamo, Italy | Recruiting |
| Research site | Foggia, Italy | Recruiting |
| Research Site | Foggia, Italy | Recruiting |
| Research Site | Meldola, Italy | Recruiting |
| Research site | Milan, Italy | Active Not Recruiting |
| Research Site | Milan, Italy | Recruiting |
| Research site | Modena, Italy | Active Not Recruiting |
| Research Site | Modena, Italy | Not Yet Recruiting |
| Research site | Naples, Italy | Recruiting |
| Research Site | Naples, Italy | Recruiting |
+ 12 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07607769